世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

イピリムマブ注射の世界市場成長2024-2030年


Global Ipilimumab Injection Market Growth 2024-2030

CTLA-4を阻害することで、イピリムマブはがん細胞に対する身体の免疫反応を強化し、腫瘍をより強力に攻撃できるようにする。 イピリムマブ注射剤の世界市場規模は、2024年の100万米ドルから2030年には100万米ド... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
LP Information
LPインフォメーション
2024年11月12日 US$3,660
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
83 英語

日本語のページは自動翻訳を利用し作成しています。


 

サマリー

CTLA-4を阻害することで、イピリムマブはがん細胞に対する身体の免疫反応を強化し、腫瘍をより強力に攻撃できるようにする。
イピリムマブ注射剤の世界市場規模は、2024年の100万米ドルから2030年には100万米ドルに成長すると予測されており、2024年から2030年までの年平均成長率は%であると予測されています。
LPインフォメーション株式会社(東京都千代田区/代表取締役:劉克振、以下LPI)の最新調査レポート「イピリムマブ注射液の産業予測」は、2023年のイピリムマブ注射液の世界総売上高を過去の売上高から検証し、2024年から2030年に予測されるイピリムマブ注射液の売上高を地域別・市場分野別に包括的に分析しています。イピリムマブ注射液の売上高を地域別、市場分野別、サブセクター別に分類し、世界のイピリムマブ注射液産業の詳細な分析を百万米ドル単位で提供します。
当インサイトレポートでは、世界のIpilimumab Injectionの状況を包括的に分析し、製品セグメンテーション、企業形成、収益、市場シェア、最新動向、M&A活動などに関する主要動向を明らかにします。また本レポートでは、イピリムマブ注射液のポートフォリオと能力、市場参入戦略、市場での地位、地理的な足跡に焦点を当てて、主要グローバル企業の戦略を分析し、加速する世界のイピリムマブ注射液市場におけるこれらの企業の独自の地位をより深く理解することができます。
当インサイトレポートでは、イピリムマブ注射剤の世界的な見通しを形成している主要な市場動向、促進要因、影響要因を評価し、タイプ別、用途別、地域別、市場規模別に分類して予測を行い、新たな機会のポケットを浮き彫りにします。何百ものボトムアップの定性的・定量的市場インプットに基づいた透明性の高い手法により、本調査予測は世界のイピリムマブ注射剤の現状と将来の軌道について非常にニュアンスのある見解を提供します。
イピリムマブ注射液の米国市場は、2023年の100万米ドルから2030年までに100万米ドルに増加し、2024年から2030年までの年平均成長率は%と推定される。
イピリムマブ注射液の中国市場は、2023年の百万米ドルから2030年には百万米ドルに増加し、2024年から2030年までの年平均成長率は%と推定される。
イピリムマブ注射液のヨーロッパ市場は、2023年の百万米ドルから2030年には百万米ドルに増加すると推定され、2024年から2030年までのCAGRは%である。
イピリムマブ注射液の世界的な主要企業はBristol Myers Squibb社などである。収益の面では、世界の2大企業が2023年にほぼ%のシェアを占めている。
のシェアを占めている。
当レポートでは、イピリムマブ注射剤市場の製品タイプ別、用途別、主要メーカー別、主要地域別および国別の包括的な概要、市場シェア、成長機会を紹介しています。
タイプ別セグメント
50mg/バイアル
200mg/バイアル
用途別セグメント
メラノーマ
腎細胞がん
大腸がん
肝細胞がん
非小細胞肺がん
悪性胸腺中皮腫
その他
本レポートではまた、市場を地域別に分けています:
南北アメリカ
アメリカ
カナダ
メキシコ
ブラジル
APAC
中国
日本
韓国
東南アジア
インド
オーストラリア
ヨーロッパ
ドイツ
フランス
英国
イタリア
ロシア
中東・アフリカ
エジプト
南アフリカ
イスラエル
トルコ
GCC諸国
以下の企業は、一次専門家から収集したインプットと、企業のカバレッジ、製品ポートフォリオ、市場浸透度の分析に基づいて選択されています。
ブリストル・マイヤーズ スクイブ
本レポートで扱う主な質問
イピリムマブ注射液の世界市場10年見通しは?
イピリムマブ注射液の世界市場および地域別市場成長の要因は何か?
市場別、地域別に最も急成長する技術は何か?
イピリムマブ注射液の市場機会は最終市場規模によってどのように異なるのか?
イピリムマブ注射液のタイプ別、用途別の内訳は?



ページTOPに戻る


目次

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Ipilimumab Injection Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Ipilimumab Injection by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Ipilimumab Injection by Country/Region, 2019, 2023 & 2030
2.2 Ipilimumab Injection Segment by Type
2.2.1 50mg per Vial
2.2.2 200mg per Vial
2.3 Ipilimumab Injection Sales by Type
2.3.1 Global Ipilimumab Injection Sales Market Share by Type (2019-2024)
2.3.2 Global Ipilimumab Injection Revenue and Market Share by Type (2019-2024)
2.3.3 Global Ipilimumab Injection Sale Price by Type (2019-2024)
2.4 Ipilimumab Injection Segment by Application
2.4.1 Melanoma
2.4.2 Renal Cell Carcinoma
2.4.3 Colorectal Cancer
2.4.4 Hepatocellular Carcinoma
2.4.5 Non-small Cell Lung Cancer
2.4.6 Malignant Thymic Mesothelioma
2.4.7 Other
2.5 Ipilimumab Injection Sales by Application
2.5.1 Global Ipilimumab Injection Sale Market Share by Application (2019-2024)
2.5.2 Global Ipilimumab Injection Revenue and Market Share by Application (2019-2024)
2.5.3 Global Ipilimumab Injection Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Ipilimumab Injection Breakdown Data by Company
3.1.1 Global Ipilimumab Injection Annual Sales by Company (2019-2024)
3.1.2 Global Ipilimumab Injection Sales Market Share by Company (2019-2024)
3.2 Global Ipilimumab Injection Annual Revenue by Company (2019-2024)
3.2.1 Global Ipilimumab Injection Revenue by Company (2019-2024)
3.2.2 Global Ipilimumab Injection Revenue Market Share by Company (2019-2024)
3.3 Global Ipilimumab Injection Sale Price by Company
3.4 Key Manufacturers Ipilimumab Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ipilimumab Injection Product Location Distribution
3.4.2 Players Ipilimumab Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Ipilimumab Injection by Geographic Region
4.1 World Historic Ipilimumab Injection Market Size by Geographic Region (2019-2024)
4.1.1 Global Ipilimumab Injection Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Ipilimumab Injection Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Ipilimumab Injection Market Size by Country/Region (2019-2024)
4.2.1 Global Ipilimumab Injection Annual Sales by Country/Region (2019-2024)
4.2.2 Global Ipilimumab Injection Annual Revenue by Country/Region (2019-2024)
4.3 Americas Ipilimumab Injection Sales Growth
4.4 APAC Ipilimumab Injection Sales Growth
4.5 Europe Ipilimumab Injection Sales Growth
4.6 Middle East & Africa Ipilimumab Injection Sales Growth
5 Americas
5.1 Americas Ipilimumab Injection Sales by Country
5.1.1 Americas Ipilimumab Injection Sales by Country (2019-2024)
5.1.2 Americas Ipilimumab Injection Revenue by Country (2019-2024)
5.2 Americas Ipilimumab Injection Sales by Type (2019-2024)
5.3 Americas Ipilimumab Injection Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ipilimumab Injection Sales by Region
6.1.1 APAC Ipilimumab Injection Sales by Region (2019-2024)
6.1.2 APAC Ipilimumab Injection Revenue by Region (2019-2024)
6.2 APAC Ipilimumab Injection Sales by Type (2019-2024)
6.3 APAC Ipilimumab Injection Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Ipilimumab Injection by Country
7.1.1 Europe Ipilimumab Injection Sales by Country (2019-2024)
7.1.2 Europe Ipilimumab Injection Revenue by Country (2019-2024)
7.2 Europe Ipilimumab Injection Sales by Type (2019-2024)
7.3 Europe Ipilimumab Injection Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Ipilimumab Injection by Country
8.1.1 Middle East & Africa Ipilimumab Injection Sales by Country (2019-2024)
8.1.2 Middle East & Africa Ipilimumab Injection Revenue by Country (2019-2024)
8.2 Middle East & Africa Ipilimumab Injection Sales by Type (2019-2024)
8.3 Middle East & Africa Ipilimumab Injection Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ipilimumab Injection
10.3 Manufacturing Process Analysis of Ipilimumab Injection
10.4 Industry Chain Structure of Ipilimumab Injection
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ipilimumab Injection Distributors
11.3 Ipilimumab Injection Customer
12 World Forecast Review for Ipilimumab Injection by Geographic Region
12.1 Global Ipilimumab Injection Market Size Forecast by Region
12.1.1 Global Ipilimumab Injection Forecast by Region (2025-2030)
12.1.2 Global Ipilimumab Injection Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Ipilimumab Injection Forecast by Type (2025-2030)
12.7 Global Ipilimumab Injection Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Bristol Myers Squibb
13.1.1 Bristol Myers Squibb Company Information
13.1.2 Bristol Myers Squibb Ipilimumab Injection Product Portfolios and Specifications
13.1.3 Bristol Myers Squibb Ipilimumab Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Bristol Myers Squibb Main Business Overview
13.1.5 Bristol Myers Squibb Latest Developments
14 Research Findings and Conclusion

 

ページTOPに戻る


 

Summary

Ipilimumab injection is a cancer immunotherapy used primarily for treating melanoma, and it is also utilized for other cancers like renal cell carcinoma.By blocking CTLA-4, ipilimumab enhances the body's immune response against cancer cells, allowing for a more vigorous attack on tumors.
The global Ipilimumab Injection market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of %from 2024 to 2030.
LP Information, Inc. (LPI) ' newest research report, the “Ipilimumab Injection Industry Forecast” looks at past sales and reviews total world Ipilimumab Injection sales in 2023, providing a comprehensive analysis by region and market sector of projected Ipilimumab Injection sales for 2024 through 2030. With Ipilimumab Injection sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Ipilimumab Injection industry.
This Insight Report provides a comprehensive analysis of the global Ipilimumab Injection landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Ipilimumab Injection portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Ipilimumab Injection market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Ipilimumab Injection and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Ipilimumab Injection.
United States market for Ipilimumab Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
China market for Ipilimumab Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Europe market for Ipilimumab Injection is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.
Global key Ipilimumab Injection players cover Bristol Myers Squibb, etc. In terms of revenue, the global two largest companies occupied for a share nearly
% in 2023.
This report presents a comprehensive overview, market shares, and growth opportunities of Ipilimumab Injection market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
50mg per Vial
200mg per Vial
Segmentation by Application:
Melanoma
Renal Cell Carcinoma
Colorectal Cancer
Hepatocellular Carcinoma
Non-small Cell Lung Cancer
Malignant Thymic Mesothelioma
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Bristol Myers Squibb
Key Questions Addressed in this Report
What is the 10-year outlook for the global Ipilimumab Injection market?
What factors are driving Ipilimumab Injection market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Ipilimumab Injection market opportunities vary by end market size?
How does Ipilimumab Injection break out by Type, by Application?



ページTOPに戻る


Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Ipilimumab Injection Annual Sales 2019-2030
2.1.2 World Current & Future Analysis for Ipilimumab Injection by Geographic Region, 2019, 2023 & 2030
2.1.3 World Current & Future Analysis for Ipilimumab Injection by Country/Region, 2019, 2023 & 2030
2.2 Ipilimumab Injection Segment by Type
2.2.1 50mg per Vial
2.2.2 200mg per Vial
2.3 Ipilimumab Injection Sales by Type
2.3.1 Global Ipilimumab Injection Sales Market Share by Type (2019-2024)
2.3.2 Global Ipilimumab Injection Revenue and Market Share by Type (2019-2024)
2.3.3 Global Ipilimumab Injection Sale Price by Type (2019-2024)
2.4 Ipilimumab Injection Segment by Application
2.4.1 Melanoma
2.4.2 Renal Cell Carcinoma
2.4.3 Colorectal Cancer
2.4.4 Hepatocellular Carcinoma
2.4.5 Non-small Cell Lung Cancer
2.4.6 Malignant Thymic Mesothelioma
2.4.7 Other
2.5 Ipilimumab Injection Sales by Application
2.5.1 Global Ipilimumab Injection Sale Market Share by Application (2019-2024)
2.5.2 Global Ipilimumab Injection Revenue and Market Share by Application (2019-2024)
2.5.3 Global Ipilimumab Injection Sale Price by Application (2019-2024)
3 Global by Company
3.1 Global Ipilimumab Injection Breakdown Data by Company
3.1.1 Global Ipilimumab Injection Annual Sales by Company (2019-2024)
3.1.2 Global Ipilimumab Injection Sales Market Share by Company (2019-2024)
3.2 Global Ipilimumab Injection Annual Revenue by Company (2019-2024)
3.2.1 Global Ipilimumab Injection Revenue by Company (2019-2024)
3.2.2 Global Ipilimumab Injection Revenue Market Share by Company (2019-2024)
3.3 Global Ipilimumab Injection Sale Price by Company
3.4 Key Manufacturers Ipilimumab Injection Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Ipilimumab Injection Product Location Distribution
3.4.2 Players Ipilimumab Injection Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2019-2024)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Ipilimumab Injection by Geographic Region
4.1 World Historic Ipilimumab Injection Market Size by Geographic Region (2019-2024)
4.1.1 Global Ipilimumab Injection Annual Sales by Geographic Region (2019-2024)
4.1.2 Global Ipilimumab Injection Annual Revenue by Geographic Region (2019-2024)
4.2 World Historic Ipilimumab Injection Market Size by Country/Region (2019-2024)
4.2.1 Global Ipilimumab Injection Annual Sales by Country/Region (2019-2024)
4.2.2 Global Ipilimumab Injection Annual Revenue by Country/Region (2019-2024)
4.3 Americas Ipilimumab Injection Sales Growth
4.4 APAC Ipilimumab Injection Sales Growth
4.5 Europe Ipilimumab Injection Sales Growth
4.6 Middle East & Africa Ipilimumab Injection Sales Growth
5 Americas
5.1 Americas Ipilimumab Injection Sales by Country
5.1.1 Americas Ipilimumab Injection Sales by Country (2019-2024)
5.1.2 Americas Ipilimumab Injection Revenue by Country (2019-2024)
5.2 Americas Ipilimumab Injection Sales by Type (2019-2024)
5.3 Americas Ipilimumab Injection Sales by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Ipilimumab Injection Sales by Region
6.1.1 APAC Ipilimumab Injection Sales by Region (2019-2024)
6.1.2 APAC Ipilimumab Injection Revenue by Region (2019-2024)
6.2 APAC Ipilimumab Injection Sales by Type (2019-2024)
6.3 APAC Ipilimumab Injection Sales by Application (2019-2024)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Ipilimumab Injection by Country
7.1.1 Europe Ipilimumab Injection Sales by Country (2019-2024)
7.1.2 Europe Ipilimumab Injection Revenue by Country (2019-2024)
7.2 Europe Ipilimumab Injection Sales by Type (2019-2024)
7.3 Europe Ipilimumab Injection Sales by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Ipilimumab Injection by Country
8.1.1 Middle East & Africa Ipilimumab Injection Sales by Country (2019-2024)
8.1.2 Middle East & Africa Ipilimumab Injection Revenue by Country (2019-2024)
8.2 Middle East & Africa Ipilimumab Injection Sales by Type (2019-2024)
8.3 Middle East & Africa Ipilimumab Injection Sales by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Ipilimumab Injection
10.3 Manufacturing Process Analysis of Ipilimumab Injection
10.4 Industry Chain Structure of Ipilimumab Injection
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Ipilimumab Injection Distributors
11.3 Ipilimumab Injection Customer
12 World Forecast Review for Ipilimumab Injection by Geographic Region
12.1 Global Ipilimumab Injection Market Size Forecast by Region
12.1.1 Global Ipilimumab Injection Forecast by Region (2025-2030)
12.1.2 Global Ipilimumab Injection Annual Revenue Forecast by Region (2025-2030)
12.2 Americas Forecast by Country (2025-2030)
12.3 APAC Forecast by Region (2025-2030)
12.4 Europe Forecast by Country (2025-2030)
12.5 Middle East & Africa Forecast by Country (2025-2030)
12.6 Global Ipilimumab Injection Forecast by Type (2025-2030)
12.7 Global Ipilimumab Injection Forecast by Application (2025-2030)
13 Key Players Analysis
13.1 Bristol Myers Squibb
13.1.1 Bristol Myers Squibb Company Information
13.1.2 Bristol Myers Squibb Ipilimumab Injection Product Portfolios and Specifications
13.1.3 Bristol Myers Squibb Ipilimumab Injection Sales, Revenue, Price and Gross Margin (2019-2024)
13.1.4 Bristol Myers Squibb Main Business Overview
13.1.5 Bristol Myers Squibb Latest Developments
14 Research Findings and Conclusion

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(医薬)の最新刊レポート


よくあるご質問


LP Information社はどのような調査会社ですか?


LP Informationは通信、エネルギー、医薬をはじめとする広範な市場の調査とレポート出版を行っている調査会社です。 もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/12/05 10:26

151.38 円

159.59 円

194.97 円

ページTOPに戻る